Clinical Trials Logo

Stage I Kidney Wilms Tumor clinical trials

View clinical trials related to Stage I Kidney Wilms Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT06401330 Not yet recruiting - Clinical trials for Stage III Kidney Wilms Tumor

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Start date: June 12, 2024
Phase: Phase 3
Study type: Interventional

This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.

NCT ID: NCT01808079 Completed - Clinical trials for Stage III Kidney Wilms Tumor

Gene Analysis in Studying Susceptibility to Wilms Tumor

Start date: October 2009
Phase: N/A
Study type: Observational

This clinical trial studies gene analysis in studying susceptibility to Wilms tumor. Finding genetic markers for Wilms tumor may help identify patients who are at risk of relapse.

NCT ID: NCT00945009 Active, not recruiting - Clinical trials for Rhabdoid Tumor of the Kidney

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Start date: July 13, 2009
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.

NCT ID: NCT00352534 Active, not recruiting - Clinical trials for Stage III Kidney Wilms Tumor

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Start date: November 6, 2006
Phase: Phase 3
Study type: Interventional

This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors.Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.